# Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia

> **NCT00444951** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 450 (actual)

## Conditions studied

- Neisseria Meningitidis
- Meningococcal Infections

## Interventions

- **BIOLOGICAL:** Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine
- **BIOLOGICAL:** Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine
- **BIOLOGICAL:** Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine

## Key facts

- **NCT ID:** NCT00444951
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-02
- **Final completion:** 2009-02
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2015-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00444951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00444951, "Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00444951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*